

ETHICS GUIDANCE

FOR THE IMPLEMENTATION
OF THE END TB STRATEGY

THE
END TB
STRATEGY



World Health
Organization

Ethics guidance for the implementation of the End TB strategy

ISBN 978–92–4–151211–4

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Ethics guidance for the implementation of the End TB strategy. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.


The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

Editing and design by Inis Communication – www.iniscommunication.com

WHO/HTM/TB/2017.07.



ETHICS GUIDANCE

FOR THE IMPLEMENTATION
OF THE END TB STRATEGY

THE
END TB
STRATEGY



World Health
Organization



Contents

Forewordiv
Acknowledgements	v
Abbreviations and acronyms	vii
Introduction	viii
Methodsix
Overarching goals and values.	1
1. Ending TB as a matter of social justice	1
2. Ethics and human rights: key foundations of the End TB Strategy	2
3. Guiding principles and values to help end TB	5
4. The obligation to provide access to TB services	7
Section one – Integrated, patient-centred care and prevention. . .	11
5. Education, counselling and the role of consent.	11
6. Diagnosis in the absence of treatment services.	15
7. Addressing latent TB infection	16
8. Supporting patients to adhere to treatment and other health care recommendations	18
9. Patient treatment and care when recommended TB treatment regimens are not feasible	23
10. Palliative and end-of-life care	25
11. Children.	27
12. Prisoners	29
13. Migrants	30





Section two – Bold policies and supportive systems 34

- 14. Infection prevention and control 34
- 15. Isolation and involuntary isolation 35
- 16. Screening 39
- 17. Surveillance 40
- 18. Compassionate use and expanded access to TB drugs 41
- 19. Health care workers’ rights and responsibilities. 42

Section three – Research and emerging technologies 45

- 20. TB and health information technology 45
- 21. New frontiers in TB care and control. 48
- 22. Rapid sharing of data 53

References 55

Bibliography 62



Foreword

The World Health Organization (WHO) End TB Strategy is fully aligned with the framework of the Sustainable Development Goals (SDGs). Both require due attention to equity, human rights and ethics. In fact, “protecting human rights, ethics and equity” is one of the four key principles of the WHO End TB Strategy. The SDG agenda itself is inspired by a simple motto: “Leave no one behind”. Ensuring that these essential principles guide the implementation of the *End TB Strategy* is a must, especially when tuberculosis (TB) is rampant among the most vulnerable and marginalized populations everywhere in the world.

Applying these principles in the field is not always easy, as patients, communities, health workers, and other TB stakeholders face conflicts and even ethical dilemmas when implementing the Strategy. This guidance aims at addressing that very challenge, and represents the work of people and experts belonging to many constituencies: from national TB programmes to civil society, affected individuals and communities as well as experts in public health, ethics, health law and human rights. We are grateful for their essential contributions and for their engagement in supporting the development of this document. We hope that there is rapid and wide uptake of this guidance, which is designed to help ensure that the implementation of the End TB Strategy is in line with sound ethical standards.

In this new millennium, it is widely recognized that science and ethics need to work together very closely to guide our action. Only when evidence-based, effective interventions are informed by a sound ethical framework, and respect and protect human rights, will we be successful in reaching our ambitious goals of ending the TB epidemic and the associated human suffering, “leaving no one behind”.

Dr Mario Raviglione

Director, Global TB Programme
World Health Organization

Acknowledgements

The production of this guidance was managed by Ernesto Jaramillo and Andreas Reis, under the supervision of Abha Saxena and Karin Weyer, and the overall direction of Mario Raviglione, Director of the Global TB Programme and Ties Boerma, Director of the Department of Information, Evidence and Research. The contribution of other WHO staff – Marie-Charlotte Bouësseau, Joan Dzenowagis, Knut Lönnroth, Vasee Moorthy, Nobuyuki Nishikiori, Diana Weil, and Matteo Zignol – in the production of this guidance document is acknowledged. Several WHO interns, who provided support to the work during (and partly after) their internship, are also gratefully acknowledged: Chavy Arora, Antonia Fitzek, Sophie M. Hermanns, Patrik Hummel and Jan Nieke.

Chief Editors

Diego S. Silva (Simon Fraser University, Canada)

Ernesto Jaramillo (WHO)

Andreas Reis (WHO)

WHO gratefully acknowledges contributions of co-authors and peer-reviewers of the different sections; and the experts on the External Review Group who provided inputs at different stages in the process.

Contributors

Nisha Ahamed (Rutgers New Jersey Medical School Global TB Institute, USA), Tammam Aloudat (Médecins Sans Frontières, Switzerland), Farhana Amanullah (Indus Hospital, Pakistan) Ronald Bayer (Columbia University, USA), Anant Bhan (Consultant, India), Frank Aday Bonsu (Ministry of Health, Ghana), Tsira Chakhaia (Tbilisi, Georgia), Lucy Chesire (TB ACTION Group, Kenya), Brian Citro (University of Chicago Law School, USA), Stéphanie Dagon (University of Zurich, Switzerland), Colleen Daniels (Stop TB Partnership, Switzerland), Manfred Danilovits (Ministry of Health, Estonia), Poonam Dhavan (International Organization for Migration, Switzerland), Bernice Elger (University of Geneva, Switzerland), Kathy Fiekert (KNCV Tuberculosis Foundation, the Netherlands), Andreas Frewer (University of Erlangen-Nürnberg, Germany), Mike Frick (Treatment Action Group, USA), Michel Gasana (Ministry of Health, Rwanda), Ken Goodman (University of Miami, USA), Andrei Mariandyshev (Northern State Medical University, Russian Federation), Sundari Mase (United States Centers for Disease Control and Prevention), Norbert Ndjeka (Department of Health of South Africa), Naranbat Nyamdavaa (on behalf of the national TB control programme, Mongolia), Christoph Ostgathe (University of Erlangen-Nürnberg, Germany), John Porter (London School of Hygiene & Tropical Medicine, UK), Ejaz Qadeer (Federal Ministry of Health, Pakistan), Lee Reichman (Rutgers New Jersey Medical School Global TB Institute, USA), Maria Rodriguez (Ministry of Health, Dominican Republic), Abdul Hamid Salim (TB consultant, Bangladesh), Julia Tainijoki-Seyer (World Medical Association, France), Carrie Tudor (International Council of Nurses, Switzerland), Verina Wild (University of Zurich, Switzerland), Justin Wong Yun Yaw (Ministry of Health, Brunei Darussalam).

External reviewers

Oumou Younoussa Ba-Sow (National Hospital Ignace Deen, Guinea), Angus Dawson (University of Sydney, Australia), Justin Denholm (Victorian Tuberculosis Program, Australia), Paula Fujiwara (International Union Against Tuberculosis and Lung Disease, France), Tina Garani-Papadatos (University of Athens, Greece), Dirceu Greco (Federal University of Minas Gerais, Brazil), Michael Selgelid (Monash University, Australia), Ross Upshur (University of Toronto, Canada), Kitty van Weezenbeek (KNCV Tuberculosis Foundation, the Netherlands), Cong Yali (University of Beijing, China), Ma. Eloisa C. Zepeda-Teng (Institute on Disability and Public Policy, the Philippines).

Funders

Funding from the United States Agency for International Development (USAID), through the USAID–WHO Consolidated Grants No. GHA-G-00–09–00003/US-2015–827 is gratefully acknowledged.

The co-authors, and the institutions where they work, contributed their time to the drafting of chapters, follow-up editing and review of the final document; this support is also gratefully appreciated. Being listed as a contributor or external reviewer does not necessarily indicate endorsement of this document.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26515

